Sigyn Therapeutics, Inc. (SIGY)
Sigyn Therapeutics, Inc. operates as a therapeutic technology enterprise currently in its development phase. The company's core innovation is Sigyn Therapy, an advanced blood purification system designed to overcome the limitations of existing drugs and medical devices used to treat severe inflammatory disorders. A key focus is on sepsis, which represents a major cause of hospital-related deaths. Furthermore, Sigyn Therapeutics is actively evaluating the potential of Sigyn Therapy to address a broad spectrum of other therapeutic targets, including bacterial endotoxins, peptidoglycan, and lipoteichoic acid; various viral pathogens; harmful hepatic toxins; CytoVesicles; and significant pro-inflammatory cytokines such as tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6. The company is headquartered in San Diego, California.
Sector: Surgical & Medical Instruments & Apparatus
Industry: Biotechnology
Sigyn Therapeutics, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 1.61M shares outstanding
USSigyn Therapeutics, Inc. operates as a therapeutic technology enterprise currently in its development phase.
The company's core innovation is Sigyn Therapy, an advanced blood purification system designed to overcome the limitations of existing drugs and medical devices used to treat severe inflammatory disorders. A key focus is on sepsis, which represents a major cause of hospital-related deaths. Furthermore, Sigyn Therapeutics is actively evaluating the potential of Sigyn Therapy to address a broad spectrum of other therapeutic targets, including bacterial endotoxins, peptidoglycan, and lipoteichoic acid; various viral pathogens; harmful hepatic toxins; CytoVesicles; and significant pro-inflammatory cytokines such as tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6.
The company is headquartered in San Diego, California.
Leadership
James A. Joyce
Co-Founder, Chairman, Chief Executive Officer, Inventor & Interim Chief Financial Officer
Craig Roberts
Co-Founder, Chief Technology Officer & Director
Employees
4
Country
US
Sector
Healthcare
Website
sigyntherapeutics.com
| Name | Shares | % | Source |
|---|---|---|---|
Howard Capital Management Group, LLC | 53.0K | 3.3% | 13F |
Top institutional holders
based on 1.61M shares outstanding
US30d Avg
13.71K
60d Avg
19.93K
90d Avg
24.44K